Hajifathali A, Parkhideh S, Kazemi MH, Chegeni R, Roshandel E, Gholizadeh M
Cell Mol Life Sci 77:17451770 Lv S, Sylvestre M, Prossnitz AN, Yang LF, Pun SH (2021) Design of polymeric carriers for intracellular peptide delivery in oncology applications
Local Irritation Approximately 30% of patients using dihydroergotamine mesylate nasal spray (compared to 9% of placebo patients) have reported irritation in the nose, throat, and/or disturbances in taste
I rarely don't experience pain no matter where I inject
We're here to support both practices and patients, every step of the way
Switching GLP-1 medications is a conversation for your prescribing provider, but tirzepatide represents an option worth discussing if muscle preservation is a primary concern